LGI1 and encephalitis: Nine miRNAs (miR-301a-5p, miR-21-5p, miR-128-5p, miR-155-5p, miR-34a-5p, miR-326-5p, miR-132-5p, miR-29b-5p, and miR-20a-5p) were selected for further validation using an independent cohort of 6 patients with anti-NMDA receptor encephalitis, 6 patients with anti-GABAB receptor encephalitis, 6 patients with anti-LGI1 encephalitis, 6 patients with anti-CASPR2 encephalitis, and 6 control individuals.